Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

MRC Geriatric Services Inc

Neither a doctor nor a teaching hospital

Research payments

$688,092

99 payments

Through program year 2025, MRC Geriatric Services Inc is reported as receiving $688,092 in research payments, across 99 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $241,571 24
2024 Research $48,016 5
2023 Research $132,732 11
2022 Research $133,216 21
2021 Research $77,621 9
2020 Research $29,280 16
2019 Research $25,656 13

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $211,359 10 payments
  2. AbbVie, Inc. $194,382 17 payments
  3. Janssen Research & Development, LLC $187,800 50 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $49,620 4 payments
  5. Sage Therapeutics, Inc. $31,932 15 payments
  6. Supernus Pharmaceuticals, Inc. $11,000 2 payments
  7. ACADIA Pharmaceuticals Inc $2,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $129,131 9 payments
  2. Proof of concept and DRF in BPD $115,161 5 payments
  3. A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression $107,886 16 payments
  4. PoCC study in patients with PTSD $68,189 3 payments
  5. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $43,236 25 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $32,539 2 payments
  7. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $31,932 15 payments
  8. Phase II dose finding trial in monotherapy for MDD $28,009 2 payments
  9. M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $27,102 4 payments
  10. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $18,385 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record